Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

When Novo Nordisk publishes third-quarter results next week investors and analysts are hoping the company will clarify when limits on the supply of starter doses of its weight-loss drug Wegovy in the United States will cease.

Novo investors seek clarity on Wegovy weight-loss drug shortages

Novo Nordisk has reported strong revenue and profit growth over the past five years. The company recently upgraded its guidance for 2023.

Demand for Ozempic and Wegovy Is Through the Roof. Here's Why it Can Go Even Higher.

Novo Nordisk (NYSE:NVO) is scheduled to report earnings on November 2 before the opening bell The Street consensus for Novo Nordisk (NYSE:NVO) is earnings of $0.71 per share on revenue of $7.91 billion, compared to $0.90 per share on revenue of $6.47 billion a year earlier.  Ozempic has seen a huge surge in sales, leading the company to increase its annual sales growth guidance earlier this month.

Novo Nordisk's Ozempic to take center stage when the pharma giant reports 3Q earnings next week

NVO's obesity/diabetes drug, Wegovy/Ozempic, is projected to outperform the best-selling drug of all time, Humira, with an estimated $38.5B in annual sales by 2030. This has led to the stock's inflated P/E premium near to the pharmaceutical leaders, due to the market's optimism about its profitable growth trend and potential applications for new indications. Then again, NVO's supply constraints and potential competition may limit its upside potential moving forward, made uncertain by the US government's crack-down on prescription costs.

Novo Nordisk Milks The Obesity Cash Cow - How Long Will It Last?

Novo Nordisk's portfolio of medicines has been driving strong revenue growth. However, some side effects are being discovered for some of the biotech's key products.

1 Green Flag and 1 Red Flag for Novo Nordisk

Avantor Inc.

Catalent

Danaher

DexCom

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

PepsiCo

Insulet

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

Novo Nordisk stock has tripled since 2020 and is up over 30% YTD; but there is still upside. Novo is poised to benefit from the surging demand for diabetes and obesity care, with an estimated annual TAM potential of $350-400 billion by 2030. My projections suggest that Novo Nordisk could double its revenues by 2027 and achieve $100 billion in revenues by 2030.

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative.

Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers

What happens when one company accounts for more than half of a stock index?

Ozempic Maker Novo Nordisk Has a Weight Problem

Medtronic

Moderna

With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 500 index.

3 Healthcare Stocks to Invest in for a Big Shot of Gains

Vertex Pharmaceuticals

Eli Lilly's growth is just getting started. Novo Nordisk shows no signs of slowing down, thanks to soaring sales of Ozempic and Wegovy.

3 Unstoppable Stocks to Buy Sooner Rather Than Later

Good news for Ozempic and Wegovy has enabled Novo Nordisk to outperform Apple and Microsoft in 2023. Even brighter days could lie ahead for Novo Nordisk.

This Stock-Split Stock Is Beating Both Apple and Microsoft in 2023 -- With No Artificial Intelligence (AI) Tailwind at All

Get ready for Ozem-kids! The pharmaceutical companies behind Ozempic, Mounjaro and Wegovy — which have exploded in popularity with adults looking to lose weight — are testing whether the drugs are safe for children.

Pharma firms testing weight loss drugs for kids amid Ozempic craze

Subscribers to  Chart of the Week  received this commentary on Sunday, October 15.

Options Traders Oh-Oh-Overjoyed With This Ozempic Trade

Realty Income Corp

Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.

4 Ways to Grow $100,000 Into $1 Million for Retirement

Leadership from Eli Lilly and Novo Nordisk have alluded that it could take several quarters or even years to catch up with demand. Both companies are ratcheting up supply output, which will likely lead to high manufacturing costs.

1 Thing You'd Better Know Before You Invest in the Stocks Behind Ozempic and Mounjaro

GE HealthCare Technologies Inc

GE HealthCare Technologies Inc. GEHC, -2.35% on Thursday said it is teaming up with Novo Nordisk NVO, -0.58% to develop an ultrasound treatment for type 2 diabetes and obesity.

GE HealthCare teams up with Novo Nordisk to treat diabetes without drugs

AstraZeneca

Regeneron Pharmaceuticals

Roche Holding AG

NASHVILLE, Tenn. & TARRYTOWN, N.Y. & WILMINGTON, Del. & BAGSVAERD, Denmark & BASEL, Switzerland--(BUSINESS WIRE)--Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ (“Changing Healthcare for People of African Ancestry through an InterNational Genomics & Equity”) initiative to create better health care and outcomes for all. The Together for CHANGE initiative seeks to addr.

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

Edwards Lifesciences

iShares U.S. Medical Devices ETF

Intuitive Surgical

ResMed

September-quarter earnings among medical-device makers may prove better than expected in the age of weight-loss drugs.

MedTech Earnings in the Age of Ozempic May Not Be That Bad

Novo Nordisk (NVO) aims to strengthen its pipeline by adding ocedurenone for treating uncontrolled hypertension for $1.3 billion.

Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B

Novo Nordisk (NYSE:NVO) has agreed to buy ocedurenone, a blood pressure drug for with potential applications in cardiovascular and kidney disease, the Danish group said today. Buoyed by the success of its diabetic treatments Ozempic and Wegovy, which have also been shown to cut weight and reduce heart attack risk, Novo Nordisk has surged to become Europe's biggest company.

Novo Nordisk buys blood pressure treatment to bolster diabtetes portfolio

Novo Nordisk (NVO) increases its annual sales and operating profit forecast for the second time in 2023, driven by Ozempic (semaglutide) and Wegovy.

Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain

The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.

Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 Billion—Expanding Ozempic Maker's Arsenal

Novo Nordisk (NVO) agreed to buy ocedurenone, a drug that treats uncontrolled hypertension and has the potential to be used in cases of cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion.

Novo Nordisk Buys Hypertension Drug in $1.3 Billion Deal

Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.

Novo Nordisk in $1.3 bln deal to buy hypertension drug

News for Novo Nordisk Stock (NVO)